2018
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Goodman K, Hall N, Bekaii-Saab T, Ou F, Twohy E, Meyers M, Boffa D, Mitchell K, Perry K, Frankel W, Venook A, O'Reilly E, Ilson D. Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. Journal Of Clinical Oncology 2018, 36: 4012-4012. DOI: 10.1200/jco.2018.36.15_suppl.4012.Peer-Reviewed Original Research
2017
Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Goodman K, Niedzwiecki D, Hall N, Bekaii-Saab T, Ye X, Meyers M, Mitchell-Richards K, Boffa D, Frankel W, Venook A, Hochster H, Crane C, O'Reilly E, Ilson D. Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. Journal Of Clinical Oncology 2017, 35: 1-1. DOI: 10.1200/jco.2017.35.4_suppl.1.Peer-Reviewed Original Research